SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy

Barchart · 1d ago

Prestigious honor recognizes Dr. Humes’ pioneering work in developing the Selective Cytopheretic Device (SCD) therapy, commercialized by SeaStar Medical as QUELIMMUNE® for critically ill pediatric patients with acute kidney injury (AKI)

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.